Spectrum Of Activity
Multidrug resistant tuberculosis, In combination with at least 3 other agents 400 mg PO once daily x2w, then 200 mg PO 3 times weekly for additional 22wNo renal dose adjustment
Multidrug resistant tuberculosis, In combination with at least 3 other agents
Age ≥5y BW ≥30 kg 400 mg PO once daily x2w, then 200 mg PO 3 times weekly for additional 22w
BW 15 to <30 kg 200 mg PO once daily x2w, then 100 mg PO 3 times weekly for 22wNo renal dose adjustment
Mild to moderate hepatic impairment No dose adjustment
Severe hepatic impairment Not recommended unless benefit outweighs risk
Multidrug resistant tuberculosis, in combination with at least 3 other agents.
Obtain sputum for mycobacterial culture and susceptibility testing prior to and during treatment.
Monitor liver function tests at baseline and during treatment.
Measure serum calcium, magnesium, and potassium at baseline.
Monitor ECG before initiation and during treatment.
Prolonged QT interval
Increased liver enzymes
QTc prolongating drugs
Multiple drug-drug interactions
Antimicrobial class: Diarylquinoline
Pregnancy category: B
Average serum half life: 24-30 hours (effective) 4-5 months (terminal)
Precautions: Monitoring recommended and discontinue use with appearance of a clinically significant ventricular arrhythmia or a QTc interval of greater than 500 milliseconds (confirmed by repeat ECG).
Monitoring recommended and discontinue use if aminotransferase elevations are greater than 8 times ULN, or are greater than 5 times ULN and persist beyond 2 weeks, or are accompanied by total bilirubin greater than 2 times ULN.